Slide 1: MRT-8102 Phase 1 Clinical Data Update
Degrading Proteins, Making Medicines MRT-8102 Phase 1 Clinical Data Update January 7, 2026 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts an
Slide 3: Summary of MRT-8102 Phase 1 data and hsCRP reduction
MRT-8102, a NEK7-directed molecular glue degrader (MGD), induced rapid and compelling reduction in hsCRP across all doses tested in both healthy volunteers and high-CVD risk subjects (112 subjects in total) SAD (48 healthy volunteer subjects) and MAD (40 healthy volunteer subjects) cohorts completed
Slide 4: MRT-8102 shows favorable hsCRP reduction compared to other agents
MRT-8102 shows favorable reduction of hsCRP compared to other inflammasome and IL-6 targeted agents in development MRT-8102 achieves favorable rates of hsCRP <2 mg/L compared to other inflammasome and IL-6 targeted agents MRT-8102 – Beyond an Oral IL-1/IL-6 Modality MRT-8102 data compares favorably
Slide 5: MRT-8102 induces catalytic NEK7 degradation, differentiated from SMIs
In contrast to small molecule inhibitors (SMIs), MRT-8102 induces catalytic NEK7 degradation, long-lasting inflammasome disassembly, and sustained inhibition of cytokine release MRT-8102 is Highly Differentiated over Other NLRP3/IL-1/IL-6 Pathway Modalities Due to inhibition of NLRP3 assembly, MRT-8
Slide 6: CANTOS Study Established Role of Inflammation in Cardiovascular Disease
Improving inflammatory status — independent of changes in lipid profile — reduced cumulative incidence of CV events and confirmed the role of inflammation in atherosclerotic disease CANTOS Study Established Role of Inflammation in Cardiovascular Disease 50-60% reduction in CRP noted across dose grou
Slide 7: Upstream Targeting of NLRP3/NEK7 Pathway in ASCVD
Upstream Targeting of NLRP3/NEK7 Pathway May Have Greater Potential than Downstream IL-6 Biologics in ASCVD NLRP3 activation promotes plaque growth, destabilization and CV events MRT-8102 has potential to stabilize plaques preventing thrombosis MRT-8102 ox-LDL Monocyte Foam cells NLRP3 activation Pl
Slide 8: ASCVD Presents a Substantial Market Opportunity for MRT-8102
ASCVD Presents a Substantial Market Opportunity for MRT-8102 Source: Arnett et al. Circulation (2019); Pesce et al. Front Cardiovasc Med. (2025); Alanaeme et al. Am Heart J Plus (2022); Mazhar et al. Eur Heart J. (2024) Additional interventions: lifestyle change, surgical procedures (angioplasty, en
Slide 9: MRT-8102 Profile and Interim Results of Phase I Study
MRT-8102 Profile and Interim Results of Phase I Study
Slide 10: MRT-8102 Preclinical Profile Points to Best-in-Class Potential
MRT-8102 potently degraded NEK7 MRT-8102 induced highly selective NEK7 degradation MRT-8102: Preclinical Profile Points to Best-in-Class Potential MRT-8102 exposure resulted in prolonged PD effect Cyno @ 10 mg/kg single dose MRT-8102 exposure prolonged PD effect Human PBMC @ 24h treatment DC50 = 2.5
Slide 11: MRT-8102 Phase I Study – Dose Levels and Endpoints
MRT-8102 Phase I Study – Dose Levels and Endpoints All cohorts randomized, placebo controlled (6+2) 200 mg 100 mg** 40 mg 5 mg 10 mg SAD cohorts (Part 1) One oral dose 48 participants MAD cohorts (Part 2) 7 daily oral doses 40 participants 400 mg 300 mg 200 mg* 40 mg 100 mg CRP PoC in elevated CVD r
Slide 12: MRT-8102 Achieved ~90% NEK7 Degradation in Peripheral Blood T Cells
MRT-8102 Achieved 80 – 90% NEK7 Degradation in Peripheral Blood T Cells After Single and Multiple Dose Administration Rapid and robust degradation of NEK7 noted in peripheral blood T cells (~80 - 90%) across all dose levels, consistent with preclinical findings CRP PoC MAD SAD SAD – 48 subjects (pla
Slide 13: Single Dose of MRT-8102 Led to Significant Reduction in Serum hsCRP
Baseline CRP ≥2 mg/L Single Dose of MRT-8102 Led to Significant Reduction in Serum hsCRP Baseline CRP ≥1 mg/L All subjects Maximum activity achieved at all SAD dose levels (40 – 400mg) (n=36) Baseline median CRP – 0.70 mg/L (n=7) Baseline median CRP – 3.96 mg/L (n=13) Baseline median CRP – 2.80 mg/L
Slide 14: Multiple Daily Doses Led to Sustained Reduction of Serum hsCRP
MRT-8102 induced significant reduction in serum hsCRP during multiple dose administration* Multiple Daily Doses of MRT-8102 Led to Significant and Sustained Reduction of Serum hsCRP Significant proportion of subjects achieved hsCRP reduction to <2 mg/L* * Values correspond to the best response of hs
Slide 15: Multiple Daily Doses Led to Reductions of IL-6 and IL-1β
Multiple Daily Doses of MRT-8102 Led to Reductions of IL-6 and IL-1β * Ridker PM et al. European Heart Journal (2018) Significant reduction in median IL-6 levels to below CV risk threshold noted in subjects with elevated CRP ~80% inhibition in IL-1β secretion noted in subjects with elevated CRP at b
Slide 16: MRT-8102 Reduced IL-6 Levels in CSF, Consistent with CNS Penetration
MRT-8102 Treatment Reduced IL-6 Levels in CSF Consistent with CNS Penetration Cerebrospinal fluid (CSF) Predose Day 7 75% reduction of CSF IL-6 in 2 subjects with elevated levels at baseline Cerebrospinal fluid (CSF) collection (100 mg QD) Dotted line indicates median established with CSF and plasma
Slide 17: CRP PoC (Part 3) Study in Subjects with Elevated CVD Risk
CRP PoC (Part 3) Study of MRT-8102 in Subjects with Elevated CVD Risk Double blind period - CRP endpoint: absolute reduction and reduction to <2 mg/L - CRP measurements: pre-dose, D1, D7, D14, D21, D28, D35 Placebo n ~9 MRT-8102 (40 mg) n ~27 Randomization Day 56 Day 28 Day 1 Safety follow up Study
Slide 18: Interim Analysis of CRP PoC Cohort: hsCRP and Fibrinogen Reductions
85% decrease of hsCRP after 4 weeks of dosing 94% of subjects show suppression of hsCRP to <2 mg/L* Interim Analysis of CRP PoC Cohort Suggests MRT-8102 Induced Rapid Reductions of hsCRP and Fibrinogen -80% -82% -85% -85% 85% reduction in CRP noted after 4 weeks of dosing that correlated well with s
Slide 19: Summary of Blinded Safety Data
Summary of Blinded Safety Data As of data cutoff of December 23, 2025, 112 subjects completed dosing: SAD/MAD completed, 88 HV participants enrolled Part 3 (CRP PoC) ongoing, 24 participants with elevated CVD risk and high CRP levels have concluded hsCRP assessment and are included in the analysis S
Slide 20: GFORCE-1 Study: Dose Exploration of MRT-8102
GFORCE-1 Study: Dose Exploration of MRT-8102 in Subjects with Elevated CVD Risk Double blind period CRP endpoint: absolute reduction and reduction to <2 mg/L CRP measurements: pre-dose, D1, D7, D14, D21, D28, D35 Expanded dose exploration to accelerate Phase 2 ASCVD study: Ph 2 initiation planned in
Slide 21: Additional Attractive Opportunities Exist for MRT-8102
Additional Attractive Opportunities Exist for MRT-8102 Rheumatology Gout ~3M U.S. addressable population, representing the approximately one-third of gout patients with stage 3+ CKD Gout SOC therapies are contradicted or lack safety data in CKD patients, imposing a major treatment challenge High unm
Slide 22: Summary and Pipeline Update
Summary and Pipeline Update
Slide 23: Summary of MRT-8102 Phase 1 results
SAD (48 healthy volunteer subjects) and MAD (40 healthy volunteer subjects) cohorts completed with no adverse safety signals, ~80-90% NEK7 degradation noted in T cells at all dose levels tested, and compelling reduction in hsCRP in subjects with elevated baseline CRP levels Part 3 (CRP PoC) of Phase
Slide 24: Monte Rosa Pipeline and Upcoming Milestones
Monte Rosa Pipeline and Upcoming Milestones GSPT1 Castration-resistant Prostate Cancer IL-1β/NLRP3-driven Inflammatory Diseases VAV1 Licensed to Novartis* Immune-mediated Diseases Preclinical Target Indication(s) Phase 2 initiation in 2026 Next Anticipated Milestone Phase 1 Phase 2 Phase 1 data and
Slide 25: Q&A
Q&A
Slide 26: Thank you
Thank you Mp. Monte Rosa Therapeutics